Puma Biotech Raises Guidance, Plans ALISCA Trials After Q2 Beat
PBYI has more than doubled off its 52-week low of $3.05 on elevated volume (2.2× avg).
Summary
Puma Biotechnology raised full-year revenue and net income guidance following a Q2 beat ($56.5M revenue, $8.2M net income). The company repaid long-term debt and holds $93.9M in cash. ALISCA trial enrollment begins Q3 2026 with updated breast cancer data expected Q4. Inducement RSUs were granted to five new hires. This follows the August 6 earnings report and adds forward-looking catalysts.
At the time of this announcement, PBYI was trading at $8.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $459.9M. The 52-week trading range was $3.05 to $9.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.